Hester Biosciences Ltd
Hester Biosciences Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results. The company anticipates stronger performance in the second half of FY26, aiming to cover up for a relatively damp Q2.
From Hester Biosciences Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results.
- Strategic focus on reducing dependency on tender-based revenues, aiming for a more balanced portfolio.
- Poultry healthcare division showing volume-led growth: 18% in Q2 and 10% in H1 FY26.
- New vaccine launches, such as H9N2 and avian influenza vaccine (post-manufacturing license expected by December), to enhance export and domestic sales.
- Pet Care segment expected to grow steadily, leveraging existing capacities without major capex.
- Anticipated launch of Lumpy Skin Disease (LSD) vaccine in India by mid-next financial year.
- Africa operations on track to breakeven by FY28, with long-term positioning expected to strengthen.
- Capacity expansion from capital work in progress to be commercialized by March, enabling significant vaccine production scale-up.
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major new capex planned for the next 2-3 years in the current segment; existing capacities provide a huge runway based on demand (Rajiv Gandhi, Page 12).
- Some smaller capex will occur as part of progress and renovations in existing plants, but no large-scale investments anticipated (Rajiv Gandhi, Page 12).
- Capital work in progress of INR182 crore at India plant expected to be fully capitalized by March, which will significantly enhance production capacity (Priya Gandhi, Page 3).
- Routine capital expenditure planned for the coming years apart from the existing expansion (Priya Gandhi, Page 9).
- Pet Care vaccines to be introduced using existing manufacturing facilities without major additional capex; exploring licensing opportunities before setting up dedicated facilities (Priya Gandhi, Page 6).
- Overall focus is on operational discipline, cost control, and making the business structurally stronger rather than new large capex (Priya Gandhi, Page 3).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current quarter witnessed delays in government-led immunization programs for PPR and Lumpy Skin Disease, impacting order execution and causing a 50% degrowth in Animal Healthcare division in Q2.
- These delays are timing-related and not due to lack of demand; a pickup in orders is anticipated particularly in Q4 as execution timelines normalize.
- Nepal operations were affected by timing of institutional orders and temporary disturbances but expect institutional execution to resume in H2.
- There is readiness at Hester Biosciences to meet rollout demands once government programs restart.
- No specific quantified current order book or pending orders figure was given, but management highlighted significant demand waiting to be fulfilled once institutional program activities resume.
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharmaceutical Industries Ltd (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Hester Biosciences Ltd Q2 FY26 results?
Next half of FY26 expected to show stronger performance, covering up for the subdued Q2 results. The company anticipates stronger performance in the second half of FY26, aiming to cover up for a relatively damp Q2.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
No major new capex planned for the next 2-3 years in the current segment; existing capacities provide a huge runway based on demand (Rajiv Gandhi, Page 12).
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.